diazepam has been researched along with Convulsive Generalized Seizure Disorder in 30 studies
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.
diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A Phase 3 open-label safety study (NCT02721069) evaluated long-term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters." | 9.41 | Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. ( Biton, V; Carrazana, E; Cascino, GD; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Mauney, W; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| " Continuous seizures of more than 5 min duration were randomly treated with buccal midazolam or rectal diazepam." | 9.09 | Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. ( Besag, FM; Neville, BG; Scott, RC, 1999) |
| "Of 1634 seizure clusters in pediatric patients, 186 (11." | 7.11 | Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study. ( Carrazana, E; Desai, J; Dlugos, D; Rabinowicz, AL; Tarquinio, D; Wheless, JW, 2022) |
| "An exploratory analysis from a long-term, phase 3, open-label, repeat-dose safety study of diazepam nasal spray for acute treatment of seizure clusters assessed the use of a second dose up to 24 hours after the initial dose and effectiveness in potentially reducing the number of seizures." | 5.51 | Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study. ( Carrazana, E; Cascino, GD; Dlugos, D; Hogan, RE; Liow, K; Rabinowicz, AL; Sperling, MR; Wheless, JW, 2022) |
| "A Phase 3 open-label safety study (NCT02721069) evaluated long-term safety of diazepam nasal spray (Valtoco) in patients with epilepsy and frequent seizure clusters." | 5.41 | Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy. ( Biton, V; Carrazana, E; Cascino, GD; Desai, J; Dlugos, D; Hogan, RE; Liow, K; Mauney, W; Miller, I; Rabinowicz, AL; Segal, EB; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2021) |
| " Continuous seizures of more than 5 min duration were randomly treated with buccal midazolam or rectal diazepam." | 5.09 | Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. ( Besag, FM; Neville, BG; Scott, RC, 1999) |
| "The aim of this study was to review out-of-hospital use of intranasal diazepam and midazolam for treatment of acute repetitive seizures (ARS) at a typical adult epilepsy center." | 4.12 | Use of new intranasal benzodiazepines at a typical adult epilepsy center. ( Benbadis, SR; Li, C, 2022) |
| "During her first pregnancy, a 37-year-old woman with idiopathic generalised epilepsy that was adequately controlled with lamotrigine experienced a series of epileptic seizures following an elective caesarean section." | 3.73 | [Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy]. ( Bloem, BR; Renier, WO; Voermans, NC; Zwarts, MJ, 2005) |
| " Across groups, treatment-emergent adverse event rates ranged from 66." | 3.30 | Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study. ( Carrazana, E; Misra, SN; Rabinowicz, AL; Segal, EB; Tarquinio, D; Wheless, JW, 2023) |
| "Of 1634 seizure clusters in pediatric patients, 186 (11." | 3.11 | Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study. ( Carrazana, E; Desai, J; Dlugos, D; Rabinowicz, AL; Tarquinio, D; Wheless, JW, 2022) |
| "The QOLIE-31-P includes 7 subscales: Seizure Worry, Overall QoL, Emotional Well-Being, Energy/Fatigue, Cognitive Functioning, Medication Effects, and Social Functioning; an Overall Score is calculated as a weighted composite of the 7 subscales." | 3.11 | Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study. ( Carrazana, E; Cramer, JA; Davis, C; Faught, E; Misra, SN; Rabinowicz, AL, 2022) |
| "Epilepsy is a chronic disease of the central nervous system characterized by recurrent epileptic seizures." | 3.01 | Second Generation of Antiepileptic Drugs and Oxidative Stress. ( Czuczwar, SJ; Kamieniak, M; Kośmider, K; Miziak, B, 2023) |
| "Patients with epilepsy can experience seizure clusters (acute repetitive seizures), defined as intermittent, stereotypic episodes of frequent seizure activity that are distinct from typical seizure patterns." | 3.01 | Overcoming barriers to the management of seizure clusters: ease of use and time to administration of rescue medications. ( Bougher, G; Dean, P; Desai, J; Dewar, S; Misra, SN; O'Hara, K, 2023) |
| "The primary goal of treatment for seizure clusters is cessation of the cluster to avoid progression to more severe conditions, such as prolonged seizures and status epilepticus." | 2.82 | Rescue therapies for seizure clusters: Pharmacology and target of treatments. ( Detyniecki, K; Gidal, B, 2022) |
| " The pharmacokinetic simulations of second doses predicted comparable elevations of plasma diazepam concentrations with administrations across a range of intervals after the first dose (1 min-4 h)." | 1.72 | Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis. ( Carrazana, E; Cascino, GD; Desai, J; Hogan, RE; Misra, SN; Rabinowicz, AL; Samara, E; Sperling, MR; Tarquinio, D; Vazquez, B; Wheless, JW, 2022) |
| "Beyond effectiveness for aborting seizure clusters, no data exist on how intermittent rescue therapy may impact the long-term natural course of seizure clusters." | 1.72 | Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters. ( Carrazana, E; Davis, C; Misra, SN; Peters, JM; Rabinowicz, AL; Rao, VR; Sperling, MR, 2022) |
| "In all age groups, the dosage of DZP that stopped the seizures at 5 min was not effective in terminating seizures at 60 min." | 1.32 | Diazepam terminates brief but not prolonged seizures in young, naïve rats. ( Goodkin, HP; Holmes, GL; Liu, X, 2003) |
| "an elderly patient presented with acute confusion and was found to have nonconvulsive status epilepticus." | 1.31 | Nonconvulsive status epilepticus causing acute confusion. ( Mitchell, SC; Pollock, LM, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 11 (36.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 12 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sperling, MR | 4 |
| Wheless, JW | 5 |
| Hogan, RE | 3 |
| Dlugos, D | 3 |
| Cascino, GD | 3 |
| Liow, K | 2 |
| Rabinowicz, AL | 7 |
| Carrazana, E | 7 |
| Tarquinio, D | 4 |
| Desai, J | 4 |
| Vazquez, B | 2 |
| Samara, E | 1 |
| Misra, SN | 5 |
| Cramer, JA | 1 |
| Faught, E | 1 |
| Davis, C | 2 |
| Li, C | 1 |
| Benbadis, SR | 1 |
| Rao, VR | 1 |
| Peters, JM | 1 |
| Gidal, B | 1 |
| Detyniecki, K | 1 |
| Kośmider, K | 1 |
| Kamieniak, M | 1 |
| Czuczwar, SJ | 1 |
| Miziak, B | 1 |
| O'Hara, K | 1 |
| Dewar, S | 1 |
| Bougher, G | 1 |
| Dean, P | 1 |
| McLaren, JR | 1 |
| Luo, Y | 1 |
| Kwon, H | 1 |
| Shi, W | 1 |
| Kramer, MA | 1 |
| Chu, CJ | 1 |
| Segal, EB | 2 |
| Miller, I | 1 |
| Biton, V | 1 |
| Mauney, W | 1 |
| Singh, SM | 1 |
| Sharma, B | 1 |
| Alajbegović, A | 1 |
| Loga, N | 1 |
| Alajbegović, S | 1 |
| Suljić, E | 1 |
| Goodkin, HP | 1 |
| Liu, X | 1 |
| Holmes, GL | 1 |
| Macdonald, RL | 1 |
| Bianchi, MT | 1 |
| Bianch, MT | 1 |
| Feng, H | 1 |
| Yamashita, H | 1 |
| Ohno, K | 1 |
| Inami, H | 1 |
| Shishikura, J | 1 |
| Sakamoto, S | 1 |
| Okada, M | 1 |
| Yamaguchi, T | 1 |
| Kirby, D | 1 |
| Fountain, NB | 1 |
| Quigg, M | 1 |
| Voermans, NC | 1 |
| Zwarts, MJ | 1 |
| Renier, WO | 1 |
| Bloem, BR | 1 |
| Hasegawa, S | 1 |
| Oda, Y | 1 |
| Ichiyama, T | 1 |
| Hori, Y | 1 |
| Furukawa, S | 1 |
| Reisner-Keller, LA | 1 |
| Pham, Z | 1 |
| Kuroiwa, T | 1 |
| Morita, H | 1 |
| Tanabe, H | 1 |
| Ohta, T | 1 |
| Kaplan, PW | 1 |
| Kato, H | 1 |
| Kishikawa, H | 1 |
| Emura, S | 1 |
| Takashima, T | 1 |
| Ohmori, K | 1 |
| Fujita, H | 1 |
| Scott, RC | 1 |
| Besag, FM | 1 |
| Neville, BG | 1 |
| Pollock, LM | 1 |
| Mitchell, SC | 1 |
| Butler, J | 1 |
| Lewis, M | 1 |
| Primavera, A | 1 |
| Audenino, D | 1 |
| Cocito, L | 1 |
| Ben Attia, M | 1 |
| N'Gouemo, P | 1 |
| Belaidi, M | 1 |
| Rondouin, G | 1 |
| Chicheportiche, R | 1 |
| Bowery, NG | 1 |
| Bagetta, G | 1 |
| Nisticó, G | 1 |
| Britton, P | 1 |
| Whitton, P | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A 12-Month Open-Label, Repeat-Dose Safety Study of NRL-1 in Epilepsy Subjects (DIAZ.001.05)[NCT02721069] | Phase 3 | 175 participants (Actual) | Interventional | 2016-04-11 | Completed | ||
| Intranasal Midazolam Versus Rectal Diazepam for the Home Treatment of Seizure Activity in Pediatric Patients With Epilepsy[NCT00326612] | Phase 2 | 358 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess the number of participants who received at least one dose of NRL-1 (Valtoco) during the study and comprised the safety population. (NCT02721069)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| NRL-1 5mg | 9 |
| NRL-1 10mg | 54 |
| NRL-1 15 mg | 46 |
| NRL-1 20mg | 54 |
Length of seizure. (NCT00326612)
Timeframe: 24 hours
| Intervention | Minutes (Median) |
|---|---|
| Intranasal Midazolam | 3.0 |
| Rectal Diazepam | 4.3 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 21 |
| Rectal Diazepam | 17 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 4 |
| Rectal Diazepam | 3 |
(NCT00326612)
Timeframe: 12 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 1 |
| Rectal Diazepam | 1 |
(NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 5 |
| Rectal Diazepam | 5 |
Respiratory depression was defined as intubation at Emergency Department discharge. (NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 1 |
| Rectal Diazepam | 0 |
Respiratory depression was defined as requiring oxygen at discharge from the Emergency Department. (NCT00326612)
Timeframe: 24 hours
| Intervention | participants (Number) |
|---|---|
| Intranasal Midazolam | 3 |
| Rectal Diazepam | 1 |
5 reviews available for diazepam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Rescue therapies for seizure clusters: Pharmacology and target of treatments.
Topics: Administration, Intranasal; Adolescent; Adult; Anticonvulsants; Benzodiazepines; Diazepam; Epilepsy, | 2022 |
Second Generation of Antiepileptic Drugs and Oxidative Stress.
Topics: Anticonvulsants; Carbamazepine; Diazepam; Epilepsy; Epilepsy, Generalized; Fructose; Gabapentin; Hum | 2023 |
Overcoming barriers to the management of seizure clusters: ease of use and time to administration of rescue medications.
Topics: Administration, Intranasal; Anticonvulsants; Diazepam; Epilepsy; Epilepsy, Generalized; Humans; Nasa | 2023 |
Unintentional rapid opioid detoxification: case report.
Topics: Adult; Consciousness Disorders; Critical Care; Diazepam; Drug Interactions; Emergency Service, Hospi | 2009 |
Standardized mental status testing for nonconvulsive status epilepticus.
Topics: Anticonvulsants; Diazepam; Epilepsy, Generalized; Intelligence Tests; Mental Disorders; Neuropsychol | 2004 |
6 trials available for diazepam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Use of second doses of Valtoco® (diazepam nasal spray) across 24 hours after the initial dose for out-of-hospital seizure clusters: Results from a phase 3, open-label, repeat-dose safety study.
Topics: Administration, Intranasal; Anticonvulsants; Diazepam; Epilepsy, Generalized; Hospitals; Humans; Nas | 2022 |
Safety of Diazepam Nasal Spray in Children and Adolescents With Epilepsy: Results From a Long-Term Phase 3 Safety Study.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anticonvulsants; Child; Diazepam; Double-Blind | 2022 |
Quality-of-life results in adults with epilepsy using diazepam nasal spray for seizure clusters from a long-term, open-label safety study.
Topics: Adult; Diazepam; Drug Resistant Epilepsy; Epilepsy, Generalized; Humans; Nasal Sprays; Quality of Li | 2022 |
Safety of Diazepam Nasal Spray in Pediatric Patients With Developmental Epileptic Encephalopathies: Results From a Long-term Phase 3 Safety Study.
Topics: Anticonvulsants; Brain Diseases; Child; Diazepam; Epilepsy; Epilepsy, Generalized; Humans; Lennox Ga | 2023 |
Final results from a Phase 3, long-term, open-label, repeat-dose safety study of diazepam nasal spray for seizure clusters in patients with epilepsy.
Topics: Administration, Intranasal; Adolescent; Adult; Aged; Anticonvulsants; Brain Damage, Chronic; Child; | 2021 |
Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial.
Topics: Administration, Buccal; Administration, Rectal; Adolescent; Adult; Anti-Anxiety Agents; Anticonvulsa | 1999 |
19 other studies available for diazepam and Convulsive Generalized Seizure Disorder
| Article | Year |
|---|---|
Lack of clinically relevant differences in safety and pharmacokinetics after second-dose administration of intranasal diazepam within 4 h for acute treatment of seizure clusters: A population analysis.
Topics: Administration, Intranasal; Anticonvulsants; Diazepam; Epilepsy, Generalized; Humans; Nasal Sprays; | 2022 |
Use of new intranasal benzodiazepines at a typical adult epilepsy center.
Topics: Administration, Intranasal; Adult; Anticonvulsants; Benzodiazepines; Diazepam; Epilepsy; Epilepsy, G | 2022 |
Significant improvements in SEIzure interVAL (time between seizure clusters) across time in patients treated with diazepam nasal spray as intermittent rescue therapy for seizure clusters.
Topics: Administration, Intranasal; Adult; Anticonvulsants; Brain Damage, Chronic; Diazepam; Epilepsy; Epile | 2022 |
Preliminary evidence of a relationship between sleep spindles and treatment response in epileptic encephalopathy.
Topics: Diazepam; Electroencephalography; Epilepsy, Generalized; Humans; Sleep; Sleep Stages | 2023 |
Characteristics of symptomatic epilepsy in patients with brain tumours.
Topics: Anticonvulsants; Brain Neoplasms; Carbamazepine; Diazepam; Epilepsy, Generalized; Female; Frontal Lo | 2009 |
Diazepam terminates brief but not prolonged seizures in young, naïve rats.
Topics: Age Factors; Animals; Anticonvulsants; Cerebral Cortex; Diazepam; Dose-Response Relationship, Drug; | 2003 |
Mutations linked to generalized epilepsy in humans reduce GABA(A) receptor current.
Topics: Amino Acids, Basic; Animals; Cell Line; Diazepam; Dose-Response Relationship, Drug; Drug Interaction | 2003 |
Suppression of fully kindled seizure and retardation of kindling acquisition by YM928 in the rat kindling model of epilepsy.
Topics: Animals; Anticonvulsants; Diazepam; Dose-Response Relationship, Drug; Electrodes, Implanted; Electro | 2004 |
[Epileptic seizures during childbirth in a patient with idiopathic generalised epilepsy].
Topics: Adult; Anticonvulsants; Cesarean Section; Clonazepam; Diazepam; Epilepsy; Epilepsy, Generalized; Epi | 2005 |
Ginkgo nut intoxication in a 2-year-old male.
Topics: Child, Preschool; Diazepam; Drug Therapy, Combination; Electroencephalography; Epilepsy, Generalized | 2006 |
Oral flumazenil in the treatment of epilepsy.
Topics: Administration, Oral; Clinical Trials as Topic; Diazepam; Drug Therapy, Combination; Epilepsy; Epile | 1995 |
Life threatening epilepsy in a child.
Topics: Arrhythmias, Cardiac; Child; Diazepam; Electrocardiography; Epilepsy, Generalized; Female; Humans; P | 1994 |
Nonconvulsive status epilepticus in the emergency room.
Topics: Adult; Aged; Anticonvulsants; Confusion; Diagnosis, Differential; Diazepam; Drug Therapy, Combinatio | 1996 |
Treatment of focal status epilepticus with lignocaine.
Topics: Aged; Anticonvulsants; Diazepam; Epilepsies, Partial; Epilepsy, Generalized; Humans; Lidocaine; Male | 1997 |
Nonconvulsive status epilepticus causing acute confusion.
Topics: Acute Disease; Aged; Anticonvulsants; Confusion; Diazepam; Epilepsy, Generalized; Fatal Outcome; Fem | 2000 |
Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Lorazepam or diazepam for generalised convulsions in adults.
Topics: Diazepam; Emergency Medical Services; Epilepsy, Generalized; Epilepsy, Tonic-Clonic; Evidence-Based | 2001 |
Ifosfamide encephalopathy and nonconvulsive status epilepticus.
Topics: Adult; Anticonvulsants; Antineoplastic Agents, Alkylating; Diazepam; Electroencephalography; Epileps | 2002 |
Kindling and electrode effects on the benzodiazepine receptors density of olfactory bulb and hippocampus after olfactory bulb kindling.
Topics: Animals; Diazepam; Disease Models, Animal; Electric Stimulation; Epilepsy, Generalized; Hippocampus; | 1992 |
Intrahippocampal tetanus toxin produces generalized convulsions and neurodegeneration in rats: antagonism by NMDA receptor blockers.
Topics: 2-Amino-5-phosphonovalerate; Animals; Anticonvulsants; Carbamazepine; Diazepam; Dizocilpine Maleate; | 1992 |